The impact of maternal CMV infection on birth outcomes - congenital cytomegalovirus (CMV) infection is a leading cause of birth defects and developmental disabilities in the U.S., affecting…
Ended Project Grant Awarded Last action
- Award ID
- R03AI151426
- Recipient
-
Microgen LLC UEI C6KMJUPNY6R3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $447,575
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Funding
-
- $358,060.00 Federal
- $89,515.00 Non-federal
- Place of performance
- La Marque, TX 77568, USA
Award details come from USAspending.gov.
Description
The impact of maternal CMV infection on birth outcomes - congenital cytomegalovirus (CMV) infection is a leading cause of birth defects and developmental disabilities in the U.S., affecting thousands of children each year. Notably, the majority of children acquire congenital CMV from non-primary maternal CMV infection rather than primary infection. Thus, determining the maternal serostatus in the field may further our understanding of the association between CMV infection status and worse pregnancy outcome, and risk stratify pregnant women during gestation. Current methods to detect maternal CMV serostatus are labor intensive and require sophisticated equipment, dedicated laboratory space, and trained technicians. We propose developing a point-of-care (POC) test for rapid screening of maternal CMV serostatus. A rapid, on-site test for CMV serostatus screening in biospecimens would: (1) allow for immediate counseling and confirmatory testing, and (2) avoid having to create new laboratory infrastructure for biospecimen testing. Alternatively, a rapid POC test that could be utilized during initial study screening visits would permit the efficient identification and enrollment for CMV vaccine testing.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $89,515 | $0 | |
| Amendment | $89,515 | $0 | |
| Amendment | $89,515 | $0 | |
| Original award | $89,515 | $89,515 |
Quick answers
Who received award R03AI151426?
R03AI151426 was awarded to Microgen LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 22, 2021.
How much is award R03AI151426 worth?
$447,575 has been obligated on R03AI151426: $358,060 in federal funding and $89,515 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award